Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.22.51 - cruzipain

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
Looking at the proteases from a simple perspective.
Cardiomyopathies
Identification of multiple HLA-A*0201-restricted cruzipain and FL-160 CD8+ epitopes recognized by T cells from chronically Trypanosoma cruzi-infected patients.
Chagas Disease
A cysteine protease inhibitor cures chagas' disease in an immunodeficient-mouse model of infection.
A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi.
A fragment of the major histocompatibility complex class II-associated p41 invariant chain inhibits cruzipain, the major cysteine proteinase from Trypanosoma cruzi.
Angiotensin-converting enzyme limits inflammation elicited by Trypanosoma cruzi cysteine proteases: a peripheral mechanism regulating adaptive immunity via the innate kinin pathway.
Anti-trypanosomal activity of non-peptidic nitrile-based cysteine protease inhibitors.
Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates.
Apolipoprotein A-I Truncations in Chagas Disease Are Caused by Cruzipain, the Major Cysteine Protease of Trypanosoma cruzi.
Application of Computer-Aided Drug Repurposing in the Search of New Cruzipain Inhibitors: Discovery of Amiodarone and Bromocriptine Inhibitory Effects.
Assessment of the Cruzain Cysteine Protease Reversible and Irreversible Covalent Inhibition Mechanism.
Benzimidazole inhibitors of the major cysteine protease of Trypanosoma brucei.
Catalytic Mechanism of Cruzain from Trypanosoma cruzi As Determined from Solvent Kinetic Isotope Effects of Steady-State and Pre-Steady-State Kinetics.
Characterisation of Trypanosoma cruzi populations by DNA polymorphism of the cruzipain gene detected by single-stranded DNA conformation polymorphism (SSCP) and direct sequencing.
Chemical-biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target.
Chemotherapy of Chagas disease.
Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.
Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors.
Cruzain : the path from target validation to the clinic.
Cruzipain Activates Latent TGF-? from Host Cells during T. cruzi Invasion.
Cruzipain induces autoantibodies against cardiac muscarinic acetylcholine receptors. Functional and pathological implications.
Cruzipain, a major Trypanosoma cruzi antigen, conditions the host immune response in favor of parasite.
Cruzipain, the major cysteine protease of Trypanosoma cruzi: a sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. A review.
Cruzipain, the major cysteine proteinase from the protozoan parasite Trypanosoma cruzi.
Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi.
Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection.
Cysteine protease isoforms from Trypanosoma cruzi, cruzipain 2 and cruzain, present different substrate preference and susceptibility to inhibitors.
Design, synthesis, and biochemical evaluation of novel cruzain inhibitors with potential application in the treatment of Chagas' disease.
Development of a pharmacophore for cruzain using oxadiazoles as virtual molecular probes: quantitative structure-activity relationship studies.
Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
Developments in the treatment of leishmaniasis and trypanosomiasis.
Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain.
Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach.
Displacement of the occluding loop by the parasite protein, chagasin, results in efficient inhibition of human cathepsin B.
Effects of chlorate on the sulfation process of Trypanosoma cruzi glycoconjugates. Implication of parasite sulfates in cellular invasion.
First quantum mechanics/molecular mechanics studies of the inhibition mechanism of cruzain by peptidyl halomethyl ketones.
General solid-phase method to prepare novel cyclic ketone inhibitors of the cysteine protease cruzain.
Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against Trypanosoma cruzi Infection.
Host cell invasion by Trypanosoma cruzi is potentiated by activation of bradykinin B(2) receptors.
Human T cell responses against the major cysteine proteinase (cruzipain) of Trypanosoma cruzi: role of the multifunctional alpha 2-macroglobulin receptor in antigen presentation by monocytes.
Humoral immune response to cruzipain and cardiac dysfunction in chronic Chagas disease.
Identification of a new class of nonpeptidic inhibitors of cruzain.
Identification of levothyroxine antichagasic activity through computer-aided drug repurposing.
Identification of multiple HLA-A*0201-restricted cruzipain and FL-160 CD8+ epitopes recognized by T cells from chronically Trypanosoma cruzi-infected patients.
Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease.
Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis.
Identification of Structure-Stabilizing Interactions in Enzymes: A Novel Mechanism to Impact Enzyme Activity.
Immune response to a major Trypanosoma cruzi antigen, cruzipain, is differentially modulated in C57BL/6 and BALB/c mice.
In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi.
Induction of autophagy increases the proteolytic activity of reservosomes during Trypanosoma cruzi metacyclogenesis.
Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection.
Inhibition of cysteine proteases by a natural biflavone: behavioral evaluation of fukugetin as papain and cruzain inhibitor.
Inhibitory effects of human alpha 2-macroglobulin on Trypanosoma cruzi epimastigote proteinases.
Investigation of the binding mode of a novel cruzain inhibitor by docking, molecular dynamics, ab initio and MM/PBSA calculations.
Leveraging the cruzain S3 subsite to increase affinity for reversible covalent inhibitors.
Ligand-induced conformational selection predicts the selectivity of cysteine protease inhibitors.
Looking at the proteases from a simple perspective.
Major cysteine protease (cruzipain) in Z3 sylvatic isolates of Trypanosoma cruzi from Rio de Janeiro, Brazil.
Mapping inhibitor binding modes on an active cysteine protease via nuclear magnetic resonance spectroscopy.
Mapping the S1 and S1' subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents.
Molecular description of ?-keto-based inhibitors of cruzain with activity against Chagas disease combining 3D-QSAR studies and molecular dynamics.
Molecular design aided by random forests and synthesis of potent trypanocidal agents as cruzain inhibitors for Chagas disease treatment.
Molecular Docking Studies Applied to a Dataset of Cruzain Inhibitors.
Molecular dynamics simulations of the free and inhibitor-bound cruzain systems in aqueous solvent: insights on the inhibition mechanism in acidic pH.
Molecular Features for Antitrypanosomal Activity of Thiosemicarbazones Revealed by OPS-PLS QSAR Studies.
Non-peptidic Cruzain Inhibitors with Trypanocidal Activity Discovered by Virtual Screening and In Vitro Assay.
Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy.
Novel Cruzain Inhibitors for the Treatment of Chagas' Disease.
Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease.
On the intrinsic reactivity of highly potent trypanocidal cruzain inhibitors.
Oral multicomponent DNA vaccine delivered by attenuated Salmonella elicited immunoprotection against American trypanosomiasis.
Overexpression of cruzipain, the major cysteine proteinase of Trypanosoma cruzi, is associated with enhanced metacyclogenesis.
Peptidomimetic Vinyl Heterocyclic Inhibitors of Cruzain Effect Antitrypanosomal Activity.
Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model.
Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Changas desease.
Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection.
Reversible cysteine protease inhibitors show promise for a chagas disease cure.
Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches.
Structural analysis of the N-glycans of the major cysteine proteinase of Trypanosoma cruzi. Identification of sulfated high-mannose type oligosaccharides.
Structure-Based Approaches Targeting Parasite Cysteine Proteases.
Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors.
Structure-Based Optimization of Quinazolines as Cruzain and TbrCATL Inhibitors.
Sulfates are main targets of immune responses to cruzipain and are involved in heart damage in BALB/c immunized mice.
Synthesis of a sugar-based thiosemicarbazone series and structure-activity relationship versus the parasite cysteine proteases: rhodesain, cruzain and Schistosoma mansoni cathepsin B1.
Synthesis, Biological Evaluation, and Structure-Activity Relationships of Potent Noncovalent and Nonpeptidic Cruzain Inhibitors as Anti-Trypanosoma cruzi Agents.
Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.
The crystal structure of cruzain: a therapeutic target for Chagas' disease.
The major cysteine proteinase (cruzipain) from Trypanosoma cruzi is antigenic in human infections.
The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease.
The reactivity of sera from chagasic patients against different fragments of cruzipain, the major cysteine proteinase from Trypanosoma cruzi, suggests the presence of defined antigenic and catalytic domains.
Trypanosoma cruzi Virulence Factors for the Diagnosis of Chagas' Disease.
Understanding Structure-Activity Relationships for Trypanosomal Cysteine Protease Inhibitors by Simulations and Free Energy Calculations.
Upregulation of the secretory pathway in cysteine protease inhibitor-resistant Trypanosoma cruzi.
[Cruzipain, major cysteine proteinase of Trypanosoma cruzi: sequence and genomic organization of the codifying genes]
[The chemotherapy of Chagas disease]
[The proliferative response of T cells against cruzipain in chronic chagasic cardiopathy]
Chronic Periodontitis
Design and synthesis of sensitive fluorogenic substrates specific for Lys-gingipain.
Cysticercosis
Characterization of a novel cathepsin L-like protease from Taenia solium metacestodes for the immunodiagnosis of porcine cysticercosis.
Heart Diseases
A striking common O-linked N-acetylglucosaminyl moiety between cruzipain and myosin.
HIV Infections
Cystatin C levels in sera of patients with human immunodeficiency virus infection. A new avidin-biotin ELISA assay for its measurement.
Hypersensitivity
Trypanosoma cruzi: the major cysteinyl proteinase (cruzipain) is a relevant immunogen of parasite acidic antigens (FIII).
Infections
Analysis and partial epitope mapping of human T cell responses to Trypanosoma cruzi cysteinyl proteinase.
Angiotensin-converting enzyme limits inflammation elicited by Trypanosoma cruzi cysteine proteases: a peripheral mechanism regulating adaptive immunity via the innate kinin pathway.
Antibody responses to a 33 kDa cysteine protease of Trypanosoma congolense: relationship to 'trypanotolerance' in cattle.
Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.
Congopain from Trypanosoma congolense: drug target and vaccine candidate.
Cooperative activation of TLR2 and bradykinin B2 receptor is required for induction of type 1 immunity in a mouse model of subcutaneous infection by Trypanosoma cruzi.
Cruzain and Rhodesain Inhibitors: Last Decade of Advances in Seeking for New Compounds Against American and African Trypanosomiases.
Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
Cruzipain, a major Trypanosoma cruzi antigen, conditions the host immune response in favor of parasite.
Cruzipain, a major Trypanosoma cruzi antigen, promotes arginase-2 expression and survival of neonatal mouse cardiomyocytes.
Cruzipain, the major cysteine proteinase from the protozoan parasite Trypanosoma cruzi.
Crystal Structures of TbCatB and rhodesain, potential chemotherapeutic targets and major cysteine proteases of Trypanosoma brucei.
Cystatins up-regulate nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages.
Detection of cruzipain, the major cysteine proteinase from Trypanosoma cruzi and its C-terminal extension in biological fluids during experimental infection in mice.
First quantum mechanics/molecular mechanics studies of the inhibition mechanism of cruzain by peptidyl halomethyl ketones.
Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against Trypanosoma cruzi Infection.
In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi.
Induction of antibodies reactive to cardiac myosin and development of heart alterations in cruzipain-immunized mice and their offspring.
Induction of autophagy increases the proteolytic activity of reservosomes during Trypanosoma cruzi metacyclogenesis.
Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection.
Induction of NADPH oxidase activity and reactive oxygen species production by a single Trypanosoma cruzi antigen.
Infection-associated vasculopathy in experimental chagas disease pathogenic roles of endothelin and kinin pathways.
Interactions between Trypanosoma cruzi Secreted Proteins and Host Cell Signaling Pathways.
Knockout of the gamma subunit of the AP-1 adaptor complex in the human parasite Trypanosoma cruzi impairs infectivity and differentiation and prevents the maturation and targeting of the major protease cruzipain.
Looking at the proteases from a simple perspective.
Oral multicomponent DNA vaccine delivered by attenuated Salmonella elicited immunoprotection against American trypanosomiasis.
Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model.
Proteolytic cleavage of chemokines by Trypanosoma cruzi's cruzipain inhibits chemokine functions by promoting the generation of antagonists.
Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection.
RNA Interference of Trypanosoma brucei Cathepsin B and L Affects Disease Progression in a Mouse Model.
Roles of naturally occurring protease inhibitors in the modulation of host cell signaling and cellular invasion by Trypanosoma cruzi.
The major cysteine proteinase (cruzipain) from Trypanosoma cruzi is antigenic in human infections.
The Trypanosoma cruzi protease cruzain mediates immune evasion.
Trans-sialidase overcomes many antigens to be used as a vaccine candidate against Trypanosoma cruzi.
Trypanosoma cruzi antigen immunization induces a higher B cell survival in BALB/c mice, a susceptible strain, compared to C57BL/6 B lymphocytes, a resistant strain to cardiac autoimmunity.
[Analysis of polymorphisms in the trypanothione reductase and cruzipain genes in Colombian strains of Trypanosoma cruzi]
Leishmaniasis, Cutaneous
A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major.
Liver Abscess, Amebic
Circulating antibodies to histolysain, the major cysteine proteinase of Entamoeba histolytica, in amoebic liver abscess patients.
Malaria
Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates.
Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
Structure-Based Approaches Targeting Parasite Cysteine Proteases.
Neoplasm Metastasis
Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents.
Looking at the proteases from a simple perspective.
Neoplasms
Blocking the proliferation of human tumor cell lines by peptidase inhibitors from bauhinia seeds.
In vitro evaluation of the disposition of A novel cysteine protease inhibitor.
Looking at the proteases from a simple perspective.
Non-peptidic Cruzain Inhibitors with Trypanocidal Activity Discovered by Virtual Screening and In Vitro Assay.
Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
Parasitemia
Trans-sialidase overcomes many antigens to be used as a vaccine candidate against Trypanosoma cruzi.
Parasitic Diseases
Cruzipain: An Update on its Potential as Chemotherapy Target against the Human Pathogen Trypanosoma cruzi.
Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents.
Periodontal Diseases
Isolation and characterization of a novel and potent inhibitor of Arg-gingipain from Streptomyces sp. strain FA-70.
Persistent Infection
Cysteine protease isoforms from Trypanosoma cruzi, cruzipain 2 and cruzain, present different substrate preference and susceptibility to inhibitors.
Retinal Degeneration
Cathepsin proteases mediate photoreceptor cell degeneration in Drosophila.
Schistosomiasis
Synthesis of a sugar-based thiosemicarbazone series and structure-activity relationship versus the parasite cysteine proteases: rhodesain, cruzain and Schistosoma mansoni cathepsin B1.
Sparganosis
Differential expression of the 27 kDa cathepsin L-like cysteine protease in developmental stages of Spirometra erinacei.
Starvation
Different signaling pathways are involved in cardiomyocyte survival induced by a Trypanosoma cruzi glycoprotein.
Induction of autophagy increases the proteolytic activity of reservosomes during Trypanosoma cruzi metacyclogenesis.
Thrombosis
Looking at the proteases from a simple perspective.
Tick Infestations
Recombinant interferon-gamma promotes immunoglobulin G and cytokine memory responses to cathepsin L-like cysteine proteinase of Hyalomma asiaticum and the efficacy of anti-tick.
Trypanosomiasis
Antibody responses to a 33 kDa cysteine protease of Trypanosoma congolense: relationship to 'trypanotolerance' in cattle.
Chalcone, acyl hydrazide, and related amides kill cultured Trypanosoma brucei brucei.
Trypanosomiasis, African
2H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.
Benzimidazole inhibitors of the major cysteine protease of Trypanosoma brucei.
Cruzain and Rhodesain Inhibitors: Last Decade of Advances in Seeking for New Compounds Against American and African Trypanosomiases.
Development of Novel Benzodiazepine-Based Peptidomimetics as Inhibitors of Rhodesain from Trypanosoma brucei rhodesiense.
Developments in the treatment of leishmaniasis and trypanosomiasis.
Drug combination studies of PS-1 and quercetin against rhodesain of Trypanosoma brucei rhodesiense.
Drug Synergism: Studies of Combination of RK-52 and Curcumin against Rhodesain of Trypanosoma brucei rhodesiense.
Fluorovinylsulfones and -Sulfonates as Potent Covalent Reversible Inhibitors of the Trypanosomal Cysteine Protease Rhodesain: Structure-Activity Relationship, Inhibition Mechanism, Metabolism, and In Vivo Studies.
Identification of non-peptidic cysteine reactive fragments as inhibitors of cysteine protease rhodesain.
Inhibition of Rhodesain as a Novel Therapeutic Modality for Human African Trypanosomiasis.
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
Optimization of triazine nitriles as rhodesain inhibitors: structure-activity relationships, bioisosteric imidazopyridine nitriles, and X-ray crystal structure analysis with human cathepsin L.
Optimization Strategy of Novel Peptide-Based Michael Acceptors for the Treatment of Human African Trypanosomiasis.
Repurposing a Library of Human Cathepsin L Ligands: Identification of Macrocyclic Lactams as Potent Rhodesain and Trypanosoma brucei Inhibitors.
Screening of acyl hydrazide proteinase inhibitors for antiparasitic activity against Trypanosoma brucei.
Structure, interdomain dynamics, and pH-dependent autoactivation of pro-rhodesain, the main lysosomal cysteine protease from African trypanosomes.
Structure-Based Optimization of Quinazolines as Cruzain and TbrCATL Inhibitors.
Substrate inhibition and allosteric regulation by heparan sulfate of Trypanosoma brucei cathepsin L.
Synthesis of a sugar-based thiosemicarbazone series and structure-activity relationship versus the parasite cysteine proteases: rhodesain, cruzain and Schistosoma mansoni cathepsin B1.
The Inhibition of Cysteine Proteases Rhodesain and TbCatB: a Valuable Approach to Treat Human African Trypanosomiasis.
Understanding Structure-Activity Relationships for Trypanosomal Cysteine Protease Inhibitors by Simulations and Free Energy Calculations.